These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 25429209

  • 1. Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.
    Cheng Y, Zhong J, Xiang Y, Zeng F, Cai D, Zhao L.
    Clin Interv Aging; 2014; 9():1981-6. PubMed ID: 25429209
    [Abstract] [Full Text] [Related]

  • 2. The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study.
    Meertens JH, Nienhuis HL, Lefrandt JD, Schalkwijk CG, Nyyssönen K, Ligtenberg JJ, Smit AJ, Zijlstra JG, Mulder DJ.
    PLoS One; 2016; 11(8):e0160893. PubMed ID: 27529340
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [Abstract] [Full Text] [Related]

  • 5. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
    Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada S, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S.
    Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
    Prasad K, Dhar I, Zhou Q, Elmoselhi H, Shoker M, Shoker A.
    Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
    [Abstract] [Full Text] [Related]

  • 8. Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults.
    Davis KE, Prasad C, Vijayagopal P, Juma S, Imrhan V.
    Nutr Res; 2014 Jun; 34(6):478-85. PubMed ID: 25026914
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism.
    Caspar-Bell G, Dhar I, Prasad K.
    Mol Cell Biochem; 2016 Mar; 414(1-2):171-8. PubMed ID: 26895319
    [Abstract] [Full Text] [Related]

  • 12. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
    Basta G, Del Turco S, Navarra T, Lee WM, Acute Liver Failure Study Group.
    Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
    [Abstract] [Full Text] [Related]

  • 13. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M.
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [Abstract] [Full Text] [Related]

  • 14. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S, Hartog JW, van Veldhuisen DJ, van der Meer P, Roze JF, Jaarsma T, Schalkwijk C, van der Horst IC, Hillege HL, Voors AA.
    Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
    [Abstract] [Full Text] [Related]

  • 15. Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness: impact of glycemic control with insulin and relation with clinical outcome.
    Ingels C, Derese I, Wouters PJ, Van den Berghe G, Vanhorebeek I.
    Shock; 2015 Feb; 43(2):109-16. PubMed ID: 25394242
    [Abstract] [Full Text] [Related]

  • 16. Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects.
    Biswas SK, Mudi SR, Mollah FH, Bierhaus A, Arslan MI.
    Diab Vasc Dis Res; 2013 Jul; 10(4):380-2. PubMed ID: 23520177
    [Abstract] [Full Text] [Related]

  • 17. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
    Kerkeni M, Saïdi A, Bouzidi H, Ben Yahya S, Hammami M.
    Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients.
    Yoon SJ, Park S, Park C, Chang W, Cho DK, Ko YG, Choi D, Kwon HM, Jang Y, Chung N.
    Coron Artery Dis; 2012 Mar; 23(2):85-90. PubMed ID: 22198512
    [Abstract] [Full Text] [Related]

  • 20. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ.
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.